Biomarker discovery from uveal melanoma secretomes: identification of gp100 and cathepsin D in patient serum.
There is a necessity to better characterize uveal melanoma (UM) tumors according to their metastasis potential at an early stage. In this study we report the identification of potential biomarkers by a combination of proteomics-related approaches: the characterization of UM cell secretomes, the analysis of UM autoantibodies, and the differential depleted serum proteome analysis. We describe a possible role of cathepsin D, syntenin, and gp100 in UM as potential biomarkers.
Pardo
María
M
Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, United Kingdom. fsmpp@usc.es
García
Angel
A
Antrobus
Robin
R
Blanco
María José
MJ
Dwek
Raymond A
RA
Zitzmann
Nicole
N
D000912:Antibodies, Neoplasm / Q000032:analysis / Q000097:blood; D001323:Autoantibodies / Q000032:analysis / Q000097:blood; D014408:Biomarkers, Tumor / Q000032:analysis / Q000097:blood*; D002402:Cathepsin D / Q000032:analysis / Q000097:blood*; D045744:Cell Line, Tumor; D006801:Humans; D008545:Melanoma / Q000097:blood* / Q000737:chemistry; D008562:Membrane Glycoproteins / Q000032:analysis / Q000097:blood*; D020543:Proteome / Q000737:chemistry / Q000378:metabolism; D014604:Uveal Neoplasms / Q000097:blood* / Q000737:chemistry; D058951:gp100 Melanoma Antigen
D000912:Antibodies, Neoplasm; D001323:Autoantibodies; D014408:Biomarkers, Tumor; D008562:Membrane Glycoproteins; C548637:PMEL protein, human; D020543:Proteome; D058951:gp100 Melanoma Antigen; D002402:Cathepsin D